Pherecydes Pharma, a biotechnology company specialized in precision phagotherapy designed to fight resistant and/or complex bacterial infections, recently announced the resounding success of its IPO on the Euronext Growth® Paris market. The company has just signed a contract with the United States Patent and Trademark Office (USPTO) for the granting of two patents for its phages, antipseudomonas aeruginosa and anti-e. coli, which will cover the United States.
These two new patents on the world’s leading healthcare market significantly broaden the geographic scope of our phages’ protection. This is the latest demonstration of the appropriateness of our intellectual property strategy. We will continue to protect our winning phages using this strategy that has amply proved its worth.“
Pherecydes Pharma currently holds an active portfolio of four patents, each of which covers multiple phages and their variants against targeted bacterial strains: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia Coli. While some of these patents are currently being processed, others have already been granted in major territories such as the United States, Europe, Japan, Australia, Hong-Kong and Israel.